ArticleFrontiers in microbiology2025
Global burden of lower respiratory infections attributable to cytomegalovirus, 1990-2021: a systematic analysis from the MICROBE database.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to investigate the global epidemiological characteristics and disease burden of lower respiratory infections (LRIs) attributable to cytomegalovirus (CMV) from 1990 to 2021. Methods: We systematically assessed the global burden and temporal trends of CMV-associated LRIs across different ages, sexes, geographic regions, and socioeconomic statuses using data from the MICROBE database spanning 1990-2021. Key metrics included mortality, disability-adjusted life years (DALYs), and their corresponding age-standardized rates (ASRs). Results: Globally, the number of DALYs due to CMV-attributed LRI decreased from an estimated 734,208 (95% UI: 612,175-856,241) in 1990 to 530,465 (95% UI: 469,046-591,884) in 2021, while the number of deaths increased from 16,141 (95% UI: 14,247-18,034) to 19,235 (95% UI: 17,204-21,266) over the same period. The age-standardized DALY rate (ASDR) declined from 13.89 (95% UI: 11.86-15.93) in 1990 to 6.95 (95% UI: 6.08-7.83) in 2021. Similarly, the age-standardized mortality rate (ASMR) dropped from 0.40 (95% UI: 0.35-0.44) to 0.24 (95% UI: 0.21-0.27). In 2021, the disease burden was highest in regions with low Socio-demographic Index (SDI). From 1990 to 2021, both ASMR and ASDR for CMV-attributable LRI decreased as SDI increased, and projections indicate a continued decline over the next 30 years. Conclusions: The global burden of CMV-attributable LRI has declined significantly from 1990 to 2021. However, targeted and cost-effective interventions are urgently needed to prevent and reduce the burden of CMV-associated LRI, particularly in low-SDI regions, children, and the elderly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.